General Authorization Criteria for ALL Agents and Indications:
|
|
- Jemima Lloyd
- 6 years ago
- Views:
Transcription
1 Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed by, or in consultation with, a hematologist or oncologist Medical records, including labs and weight or body surface area (BSA), to support diagnosis and dosing is submitted with request RequestedagentisdosedandadministeredwithinFood and Drug Administration (FDA)labeledrecommendations o Will not be used concomitantly with radiation AND chemotherapy o Will be administered at the appropriate time after chemotherapy OR radiation Member does not have any contraindications or hypersensitivity to the requested agent Will not be used in combination with other myeloid growth factors Additional Criteria Based on Indication: Chemotherapy-Induced Febrile Neutropenia: (Neupogen, Neulasta, a n d Leukine) Memberisreceiving chemotherapy for a NON-myeloid cancer (i.e., solid tumor, lymphoma) o For PRIMARY prophylaxis: Member meets one of the following: Chemotherapy regimen isgiven after bone marrow transplant; OR Chemotherapy regimen has >20% risk of febrile neutropenia; OR Chemotherapy regimen has 10%-20% risk of febrile neutropenia AND member has ANY of the following risk factors for febrile neutropenia: o age > 65 years o priorchemotherapyorradiationtherapy o persistent neutropenia o bonemarrowinvolvementbytumor o Recent surgery and or open wounds o Liver dysfunction (bilirubin > 2.0) o Renal dysfunction (creatinine clearance (CRCL) <50) o o For SECONDARYprophylaxis (Neupogen, Neulasta, andleukine):memberpreviouslyexperiencedfebrile neutropeniafromthesame chemotherapyregimenandreducingordelayingchemotherapydosemay compromisetreatment outcome For TREATMENT of febrile neutropenia (Leukine and Neupogen) in members who did NOT receive colony stimulating factor (CSFs) prophylaxis: Member has risk factors for poor outcomes resulting from febrile Effective: 2/1/2018 Page 1
2 neutropenia (e.g., age > 65, sepsis, severe neutropenia (absolute neutrophil count (ANC)< 100/mcL), current infection, hospitalized at onset of fever, prior episode of febrile neutropenia) Severe chronic congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia: (Neupogen) o Member has one of the following: Evidence ofinadequate bone marrow reserve (e.g.,recurrentfevers,splenomegaly,mucosal ulcers, abdominal pain) Highriskfordeveloping serious bacterialinfection (e.g., primarilysevere neutropenia,indwelling venous catheters, prior serious infections) Current bacterial infection NeutropeniarelatedtoHuman Immunodeficiency Virus(HIV) or drug therapy; ganciclovir or zidovudine induced:(neupogen and Leukine) o Prescribed by, or in consultation with an Infectious Disease Specialist, Hematologist, or Human Immunodeficiency Virus(HIV)Specialist Neupogen may also be approved if medically necessary for the following indications: o AcuteMyeloidLeukemiainmembersreceivinginductionorconsolidationchemotherapy o Mobilizationofhematopoieticprogenitorcellsbefore autologousstemcelltransplant o Mobilization of hematopoietic progenitor cells in the donor before allogenicstem cell transplant o Treatment of acute radiation exposure in members who receive myelosuppressive doses of radiation at a dose of 2 gray (Gy) o Myelodysplastic Syndrome (MDS) or aplastic anemia in a member with an absolute neutrophil count (ANC) <500 Leukine may also be approved if medically necessary for the following indications: o Acute Myeloid Leukemia after induction chemotherapy for members age 55 years or older o Bone marrowtransplantfailure orengraftmentdelay o Myeloid reconstitution after allogenic bone marrow transplant o Myeloidreconstitutionafter autologousbone marrowtransplantinmemberswithhodgkin sdisease,non- Hodgkin's lymphoma, or acute lymphocytic leukemia o Before andafter autologous peripheralblood stem celltransplantation Initial Approval: Chemotherapy-induced neutropenia (primary or secondary prophylaxis): o Approveper cycle ofchemotherapy: Up to a 14 day supply for Neupogen, and Leukine One (1) 6 mg dose of Neulasta no less than every 14 days Include refills if number of cycles is provided o Treatment of neutropenia (e.g., congenital, cyclic, or idiopathic, Human Immunodeficiency Virus (HIV), or after chemo + bone marrowtransplant(bmt)): Approve for 3 months Effective: 2/1/2018 Page 2
3 Forotherindications o Up to six months or less Renewal: Pharmacy Prior Authorization Chemotherapy-induced neutropenia (primary or secondary prophylaxis): o Recent absolute neutrophil count (ANC) showing a response to therapy o Approveper cycle ofchemotherapy: Up to a 14 day supply for Neupogen, and Leukine One (1) 6 mg dose of Neulasta no less than every 14 days Include refills if number of cycles is provided, or up to 12 months All other indications: o Recentabsolute neutrophil count (ANC), complete bloodcount (CBC), and/orplateletcounts o Approve up to one year Additional Information: Note: Neutropenia is defined as an absolute neutrophil count (ANC) of < 500 neutrophils/mcl or an absolute neutrophil count (ANC) of < 1000 neutrophils/mcl and a predicted decline to < than or equal to 500 neutrophils/mcl over the next 48 hours. Determining the riskof febrile neutropenia: A member s risk for developing neutropenic fever may be assessed prior to the use of colony stimulating factors. This may be achieved by evaluating the degree of myelosuppression of the member s chemotherapy regimen in addition to the presence of other member-relatedrisk factors. Both Infectious Diseases Society of America (IDSA)and National Comprehensive Cancer Network (NCCN)recommend thatcolony stimulating factors be consideredwhen the risk of febrileneutropeniais>20%. Dosing Table: Medication Dosing Available Dosage forms Effective: 2/1/2018 Page 3
4 Neupogen Febrile Neutropenia (FN) or acute myeloid leukemia (AML): 5 mcg/kg/day (Not given 24 hours before chemotherapy and 24 hours after) Bone marrow transplant (BMT): 10 mcg/kg/day (given 24 hrs after bone marrow transplant (BMT) and given for at least 24 hours) Vials: 300 mcg/ml, single-dose vial 480 mcg/1.6 ml, single-dose vial Prefilled Syringe 300 mcg/0.5 ml per syringe 480 mcg/0.8 ml per syringe Neulasta Leukine Peripheral Blood Progenitor Cell (PBPC): 10 mcg/kg/day; at least 4 days before and up to 7 days Severe Chronic Neutropenia: o Idiopathic neutropenia:1.2 mcg/kg/day o Cyclic neutropenia: 2.1 mcg/kg/day o Congenitalneutropenia: 6mcg/kg/day divided 2times per day Febrile Neutropenia- 5mcg/kg/day Not given 24 hours before chemotherapy and 24 hours after chemotherapy Given once per chemotherapy cycle Acute myeloid leukemia (AML): 250 mcg/m 2 /day subcutaneous (SQ) or intravenous (IV) on day 11 or 4 days following the completion of induction chemotherapy 6 mg/0.6 ml, single-dose prefilled syringe 6 mg/0.6 ml, single-dose prefilled syringe co-packaged with the Onbody Injector (Neulasta Onpro kit). 500 mcg/ml vial 250 mcg powder for injection References: 1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Myeloid Growth 2. Factors V Available at: Accessed August 16, Smith TJ, Khatcheressian J, Lyman GH, et al Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol 24: Available at: Accessed August 16, National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer- Related Infection. V Available at: Accessed Oct 5, Effective: 2/1/2018 Page 4
5 5. InfectiousDiseaseSociety ofamerica:clinicalpracticeguidelinefortheuseof AntimicrobialAgents in NeutropenicMembers with Cancer: 2010 Update by the Infectious Diseases Society of America. Available at: Accessed August 16, Zarxio (filgrastim-sndz) [package insert]. Princeton, NJ: Sandoz Inc. December Granix(tbo-filgrastim)[packageinsert].NorthWales,PA:Cephalon,Inc.July Neupogen [package insert]. Thousand Oaks,CA:Amgen, IncJune Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ, Groopman JE. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in members with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood. 1991;78: Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF Study Group. AIDS. 1996;10(14): Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF Study Group. AIDS. 1996;10(14): Table: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 20% or Higher Cancer Histology Treatment Setting Regimen Acute Lymphoblastic Leukemia (ALL) Bladder Cancer Induction Neoadjuvant, adjuvant, metastatic Prior adjuvant allowed ALL induction regimens (see NCCN guidelines) MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) CBDCa/Pac (carboplatin, paclitaxel) Breast Cancer Metastatic or relapsed Docetaxel + trastuzumab Adjuvant Adjuvant Metastatic (1st line) Metastatic (2nd line) Dose-dense AC followed by T (doxorubicin, cyclophosphamide, paclitaxel) TAC (docetaxel, doxorubicin, cyclophosphamide) AT (doxorubicin, docetaxel) Doc (docetaxel) Esophageal and Gastric Cancers Docetaxel/cisplatin/fluorouracil Effective: 2/1/2018 Page 5
6 Hodgkin Lymphoma Kidney Cancer Non-Hodgkin's Lymphoma Melanoma Diffuse large B-cell lymphoma {DLBCL], peripheral T-cell lymphomas (PTCL], 2nd line DLBCL, 2nd line, refractory PTCL, DLBCL, 2nd line DLBCL, PTCL, 2nd line, recurrent Relapsed Advanced, metastatic, or recurrent Advanced, metastatic, or recurrent BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) Doxorubicin/gemcitabine ICE (ifosfamide, carboplatin, etoposide) RICE (rituximab, ifosfamide, carboplatin, etoposide) CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab MINE (mesna, ifosfamide, novantrone, etoposide) DHAP (dexamethasone, cisplatin, cytarabine) ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine (Ara-C)) HyperCVAD + rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone + rituximab) VAPEC-B (vincristine, doxorubicin, prednisolone, etoposide, cyclophosphamide, bleomycin) Dacarbazine-based combination (dacarbazine, cisplatin, vinblastine) Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alpha) Effective: 2/1/2018 Page 6
7 Ovarian Cancer Topotecan Pancreatic Cancer Soft Tissue Sarcoma Small Cell Lung Cancer Advanced or metastatic Recurrent Paclitaxel Docetaxel FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) MAID (mesna, doxorubicin, ifosfammide, dacarbazine) Doxorubicin Ifosfamide/doxorubicin Top (topotecan) CAV (cyclophosphamide, doxorubicin, vincristine) Testicular cancer Relapsed VelP (vinblastine, ifosfamide, cisplatin) VIP (etoposide, ifosfamide, cisplatin) BEP (bleomycin, etoposide, cisplatin) TIP (paclitaxel, ifosfamide, cisplatin) Source: Smith, et al., 2006; NCCN, Table: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 19% Cancer Histolog y Occult primary - adenocarcinom a Treatment Setting Regimen Gemcitabine/docetaxel Effective: 2/1/2018 Page 7
8 Breast cancer Docetaxel every 21 days Adjuvant Adjuvant Adjuvant (taxane portion only) Adjuvant Metastatic (1st line) Metastatic (1st line) Metastatic (2nd line) CMF classic (cyclophosphamide, methotrexate, fluorouracil) CA (doxorubicin, cyclophosphamide) (60 mg/m2) (hospitalized) AC (doxorubicin, cyclophosphamide) + sequential docetaxel AC + sequential docetaxel + trastuzumab A (doxorubicin) (75) AC (doxorubicin, cyclophosphamide) CapDoc (capecitabine, docetaxel) FEC (fluorouracil, epirubicin, cyclophosphamide) + sequential docetaxel Metastatic or relapsed Paclitaxel every 21 days TC (docetaxel, cyclophosphamide) Cervical Cancer FOLFOX (fluorouracil, leucovorin, oxaliplatin) Colorectal Advanced FL (fluorouracil, leucovorin) Advanced (one prior chemo allowed) CPT-11 (irinotecan) (350 mg/m2 q 3 wk) Esophageal and Gastric Cancers Irinotecan/cisplatin Epirubicin/cisplatin/5-fluorouracil Epirubicin/cisplatin/capecitabine Head and Neck Induction Cis/Doc/5-FU (cisplatin, docetaxel, 5-fluorouracil) Multiple DT-PACE Effective: 2/1/2018 Page 8
9 myeloma (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophoaphamide/eto poside) Non-Hodgkin's lymphomas Non-Small Cell Lung Cancer AIDS-related NHL, Burkitt lymphoma, recurrent, otehr NHL subtypes AIDS-related NHL, DLBCL, recurrent DLBCL, PTCL, 2nd line DLBCL, 2nd line, Burkitt lymphoma, other NHL subtypes Advanced/metasta tic Adjuvant, advanced/metastat ic Adjuvant, advanced/metastat ic Adjuvant, advanced/metastat ic DT-PACE + bortezomib (VTD-PACE) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) EPOCH-IT chemotherapy GDP (gemcitabine, dexamethasone, cisplatin) GDP (gemcitabine, dexamethasone, cisplatin) + rituximab FMR (fludarabine, mitoxantrone, rituximab) CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin or mitoxantrone substituted for doxorubicin Cisplatin/paclitaxel Cisplatin/vinorelbine Cisplatin/docetaxel Cisplatin/etoposide Effective: 2/1/2018 Page 9
10 Adjuvant, advanced/metastat ic Advanced/metasta tic Carboplatin/paclitaxel Docetaxel Ovarian Cancer Pancreatic Cancer Prostate Cancer Small Cell Lung Cancer Testicular Cancer Uterine Sarcoma Advanced or metastatic Carboplatin/docetaxel FOLFIRINOX Cabazitaxel Etoposide/carboplatin Etoposide/carboplatin Docetaxel Effective: 2/1/2018 Page 10
Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
More informationPharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationPharmacy Medical Necessity Guidelines: Neulasta (pegfilgrastim)
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationCircle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]
04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationColony-stimulating factors
Colony stimulating factors page 1 APC/DTC Briefing Document Colony-stimulating factors Contents Conclusions from clinical evidence 1 Background 2 Clinical guidelines 2 Licensed indications 3 Clinical evidence
More informationCircle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.
10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationSubject: Granulocyte Colony Stimulating Factors
09-J0000-62 Original Effective Date: 11/15/00 Reviewed: 11/14/18 Revised: 04/01/19 Subject: Granulocyte Colony Stimulating Factors THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationGUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)
GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationAdjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationClinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295
Clinical Policy: (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationColony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)
Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Document Number: IC 0245 Last Review Date: 5/1/2018 Date of Origin: 03/31/2015 Dates Reviewed: 03/2015, 05/2015, 08/2015,
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationColony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)
Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Document Number: MODA-0375 Last Review Date: 08/06/2018 Date of Origin: 08/06/2018 Dates Reviewed: 08/2018 I. Length of
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationLCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
UnitedHealthcare Community Plan Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: CS2018D0061C Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationCo-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia
Co-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia Authors: John H. Page, Shuling Li, Julia Molony, Romina Sosa,
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
UnitedHealthcare Commercial Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHA043 Effective Date: February 1, 2019 Table of Contents Page INSTRUCTIONS FOR USE...
More informationProduct Visual Guide
Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationColony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy
clinical therapeutics Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy Charles L. Bennett, M.D., Ph.D., Benjamin Djulbegovic, M.D., Ph.D., LeAnn B. Norris, Pharm.D., and James O.
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
ell UnitedHealthcare Oxford Clinical Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHARMACY 296.2 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02.01.17 Last Review Date: 11.18 Coding Implications Revision Log Line of Business: Medicaid, HIM-Medical Benefit See Important
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationContents Please refer to Medical Policy I-4, Hemophilia Treatment for additional information.
August 2018 In This Issue Coverage Guidelines Updated for Hemophilia Treatment... 2 Coverage Criteria Revised for Nusinersen (Spinraza)... 6 Coverage Guidelines Developed for Vestronidase Alpha (Mepsevii)...
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationOPCS Classification of Interventions and Procedures Version 4.6 (April 2011)
Chemotherapy Regimens Clinical Coding Guidance OPCS-4.6 Version 1.0 Programme Sub Programme Data Standards & Products Clinical Classifications Document Record ID Key NPFIT-SHR-SHI-0318.01 Programme Director
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationClinical Policy: Pegfilgrastim (Neulasta) Reference Number: CP.CPA.127 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Neulasta) Reference Number: CP.CPA.127 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationKeywords: Antibiotic Prophylaxis; standard Dose; Chemotherapy; Cancer; Patient
Double -Control, Randomized Study of Antibiotic Prophylaxis during Standard Dose Chemotherapy in Cancer Patients Fatma Zakaria *1 and Mohamad Zakaria 2 Departments of Clinical Oncology 1 and Microbiology
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationCanadian supportive care recommendations for the management of neutropenia in patients with cancer
PRACTICE GUIDELINE SERIES Canadian supportive care recommendations for the management of neutropenia in patients with cancer C.T. Kouroukis MD MSc,* S. Chia MD, S. Verma MD, D. Robson MD, C. Desbiens MD,
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationPatient 1: Patient 2:
Appendix A Compiled by Dr. Raymond Ngeh and Dr. Robert Luk Clinical notes and PET/CT scan images of eleven patients: 1. Middle age woman has cancer of the pancreas in the body of the gland. After just
More informationOur Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Yescarta) Reference Number: CP.PHAR.XX Effective Date: 10.31.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationEssentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy
Practise Practise This tutorial introduces you to the history, goals of therapy, classification, and clinical uses of chemotherapy. It also reviews some of the barriers to successful therapy. Goals and
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationTransitioning Inpatient Chemotherapy to the Outpatient Setting
Transitioning Inpatient Chemotherapy to the Outpatient Setting A L I M C B R I D E, P H A R M D, M S, B C P S, B C O P C L I N I C A L C O O R D I N A T O R, T H E U N I V E R S I T Y O F A R I Z O N A
More informationCCC Chemotherapy Protocols V9.0
CCC Chemotherapy Protocols V9.0 General observations 3 Breast cancer 5 Gastrointestinal cancer Oesophagus 17 Gastric 19 Pancreas 22 Cholangiocarcinoma 24 Hepatocellular carcinoma 25 Neuroendocrine tumours
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below
More informationLack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia
Lack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia T. Siddiqui,I. A. Burney,A. Salam ( Departments of Medicine, The Aga Khan University
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More information